LIPUM.ST
Lipum AB (publ) [LIPUM.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LIPUM.ST Stock Summary
In the News
LIPUM.ST Financial details
Company Rating
-
Market Cap
251.76M
Income
-40.88M
Revenue
115K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
-1.64
Forward P/E
-
PEG
0.28
P/S
-
P/B
2.38
P/C
-
P/FCF
-2
Quick Ratio
4.67
Current Ratio
4.92
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.15
EPS next Y
-
EPS next Q
-
EPS this Y
-52.3%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-62.64%
-
-
-
-
SMA20
-
SMA50
-6.25%
SMA100
-6.25%
Inst Own
-
Inst Trans
-
ROA
-107%
ROE
-175%
ROC
-1.33%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.78-15.0
52W High
+2.67%
52W Low
+208%
RSI
51
Rel Volume
0.03
Avg Volume
13.86K
Volume
426
Perf Week
0.33%
Perf Month
-4.35%
Perf Quarter
6.21%
Perf Half Y
9.22%
-
-
-
-
Beta
0.111
-
-
Volatility
0.27%, 0.53%
Prev Close
0%
Price
15.4
Change
-0.65%
Company Profile
- Volume Average 13.86K
- Market Capitalization 251.76M
- Employee 5
- CEO Mr. Ola Sandborgh
- Headquarters Umeå,SE
- IPO Date 2021-04-22
-
Website
https://www.lipum.se 
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
